On mTOR nomenclature.
The neurology of mTOR.
Inhibitors of mTOR.
Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.
Staining of mTOR and phosphorylated-mTOR (p-mTOR) was documented and determined as percentage of the maximum.
mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases.
mTOR and phosphorylated-mTOR (p-mTOR) expressions were investigated by immunohistochemistry.
Insulin and IGF-1 enhance the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin pathway.
Phosphorylation of mTOR and S6 was blocked by the mTOR inhibitor rapamycin.
mTOR pathway and mTOR inhibitors as agents for cancer therapy.
Dissecting the role of mTOR: lessons from mTOR inhibitors.
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer.
mTOR signaling pathway and mTOR inhibitors in cancer therapy.
Roles of mTOR and p-mTOR in gastrointestinal stromal tumors.
Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): a tissue microarray study (TMA).
mTOR is activated by AKT phosphorylation (p-mTOR).
p-mTOR expressions strongly correlate with mTOR expressions.
[mTOR and FTY 720 inhibitors].
mTOR inhibitors: an overview.
mTOR as a target for cancer therapy.
Growing roles for the mTOR pathway.
Upstream and downstream of mTOR.
mTOR inhibitors in hematologic malignancies.
CCI-779 is an inhibitor of mTOR.
mTOR signaling to translation.
The pleiotropic effects of mTor inhibitors.
An expanding role for mTOR in cancer.
mTOR: a mediator of intracellular homeostasis.
Kinase activities associated with mTOR.
Targeting mTOR for cancer treatment.
Sirolimus, the first mTOR inhibitor.
Long-term effects of rapamycin treatment on insulin mediated phosphorylation of Akt/PKB and glycogen synthase activity.
Rapamycin is an inhibitor of mTOR.
The mammalian target of rapamycin (mTOR).
AKT and cancer--is it all mTOR?
mTOR: the mammalian target of replication.
A focus is delivered for mTOR inhibitors.
mTOR and cancer therapy.
Regulation of mTOR by phosphatidic acid?
mTOR inhibitors and unilateral edema.
Mutual regulation of hypoxia-inducible factor and mammalian target of rapamycin as a function of oxygen availability.
HIF is translationally regulated by mTOR.
mTOR inhibitors in the treatment of cancer.
mTOR, translation initiation and cancer.
mTOR signalling in human cancer.
The mTOR pathway in breast cancer.
mTOR inhibitors in ADPKD.
On the participation of mTOR in recognition memory.
PTEN/mTOR and axon regeneration.
Inhibition of mTOR in kidney cancer.
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
mTOR and p110alpha are coexpressed in melanoma.
mTOR goes to the nucleus.
SnapShot: mTOR signaling.
Rapamycin and mTOR kinase inhibitors.
Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications.
The mTOR pathway is also activated.
The expression of mTOR is activated in NSCLC.
mTOR, cancer and transplantation.
mTOR-what does it do?
Immunoregulatory functions of mTOR inhibition.
Expanding mTOR signaling.
Defining the role of mTOR in cancer.
mTOR-understanding the clinical effects.
The pharmacology of mTOR inhibition.
Targeting mTOR for cancer treatment.
The role of mTOR in bladder cancer.
Decision-making by p53 and mTOR.
Drug essentials mTOR inhibitors.
mTOR signaling at a glance.
The multiple facets of mTOR in immunity.
A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.
Activation of mTOR was not seen.
Updates of mTOR inhibitors.
Functional consequences of mTOR inhibition.
mTOR Signalling in Health and Disease.
Key factors in mTOR regulation.
mTOR, autophagy, and reprogramming.
Akt/mTOR signalling in myelination.
Deconvoluting mTOR biology.
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Sirolimus is the prototypical mTOR inhibitor.
The mTOR pathway in hepatic malignancies.
Where is mTOR and what is it doing there?
Modulating mTOR in aging and health.
The Paradox of Akt-mTOR Interactions.
mTOR expression in colorectal adenoma.
It was shown that hypoxia inhibits mTOR.
Senescence regulation by mTOR.
mTOR in aging, metabolism, and cancer.
It may be related with strengthening mTOR.
Contrasting effects of chronic, systemic treatment with mTOR inhibitors rapamycin and metformin on adult neural progenitors in mice.
Rapamycin is a pharmacological inhibitor of mTOR.
mTOR: more targets of resveratrol?
FKBPs and the Akt/mTOR pathway.
mTOR and lymphocyte metabolism.
Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
Hyperlipidemia was higher in mTOR group.
The functions of mTOR in ischemic diseases.
mTOR activity under hypoxia.
TFEBulous control of traffic by mTOR.
Found in translation of mTOR signaling.
mTOR inhibitors in cancer therapy.
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Everolimus is an oral mTOR-inhibitor.
Targeting mTOR for the treatment of AML.